DOCSLIB.ORG

Precautions Interactions Pharmacokinetics Uses and Administration

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2266 Sex Hormones and their Modulators sufficient to cause distress, has been described in a woman Preparations and is mainly excreted as peptide fragments in the faeces. given danazol for mastalgia. The hirsutism improved after About 20 to 30% of a dose is renally excreted. Degarelix is stopping the danazol.' ProprietaryPreparations (details are given in Volume B) injected to form a subcutaneous depot, and the I. Gately LE, Andes WA. Danazol and erythema multiforrne. Ann Intern Single-ingredient Preparations. Arg.: Ladoga!; Austral.: Azol; pharmacokinetics of the drug is strongly Influenced by the Med 1988; 109: 85. Danocrinet; Austria: Danokrin; Belg.: Danatrol; Braz.: Ladogal; concentration of the injected solution. After subcutaneous 2. Reynolds NJ, Sansom JE. Erythema multiforme during danazol therapy. Canad. : Cyclamen; China: Gong Fu Yi Kang (:g;ffl!jj>�); Cz. : injection of 240 mg at a concentration of 40 mg/mL, Clin Exp Dermato/ 1992; 17: 140. 3. Zawar V, Sankalecha C. Facial hirsutism following danazol therapy. Cutis Danoval; Fr.: Danatrol; Gr.: Danatrol; Hong Kong: Anargil; degarelix has a terminal half-life of about 43 to 53 days; after 2004; 74: 301-3. Azolt; Danocrine; Hung.: Danoval; India: Benzol; Danogen; maintenance doses of 80 mg as 20 mg/mL the half-life is Endozol; Gonablok; Gynadom; Gynazol; Gynodan; Ladoga!; about 28 days. Zendol; Indon.: Azol; Danocrine; Irl.: Danolt; Israel: Danol; Precautions Ital.: Danatrol; Jpn: Bonzol; Malaysia: Anargil; Azolt; Ladogal; Preparat ons Nazol; Mex. : Danalem; Ladogal; Novaprin; Neth.: Danatrol; NZ: i . Danazol should be used with caution in conditions that may ······························· ................................ Azol; D-Zolt; Philipp.: Ladoga!; Port. : Danatrol; Rus.: Danol ProprietaryPreparations (details are given in Volume B) be adversely affected by fluid retention, such as in (,!\aHon); Danoval (,!\aHoBaJJ); S.Afr. : Danogen; Ladazol; Singa­ Austral.: Firmagon; Austria: Fir­ cardiovascular, hepatic, and renal disorders; it should be pore: Azolt; Ladoga!; Nazol; Spain: Danatrol; Switz. : Danatrolt; Single-ingredient Preparations. magon; Belg.: Firmagon; Canad. : Firmagon; Cz.: Firmagon; avoided in marked dysfunction. It should also be used with Thai.: Anargil; Ectopal; Ladogal; Vabon; Turk. : Danasin; UK: Denm.: Firmagon; Fr.: Firmagon; Ger.: Firmagon; Gr.: Firma­ care in patients with diabetes mellitus, polycythaemia, Danol; Venez.: Danogen; Ladoga!. abnormal blood lipids, migraine, or epilepsy. Danazol gon; Irl. : Firmagon; Israel: Firmagon; Jpn: Gonax; Neth.: Fir­ magon; Norw.: Firmagon; Pol.: Firmagon; Port.: Finnagon; should not be given to patients with undiagnosed genital PharmacopoeialPreparations USP 36: Danazol Capsules. Swed. : Firmagon; Switz. : Firmagon; UK: Firmagon; USA: Fir­ bleeding or androgen-dependent tumours. As with other magon. 17a-alkylated compounds, there is an increased risk of liver disorders and liver function should be monitored during therapy. It should not be used in patients with a thromboembolic disorder or a history of thrombosis. Danazol should not be given during pregnancy because of a possible androgenic effect on the female fetus (see below), and non-hormonal contraception is recommended during treatment. Caution is required in children and adolescents since precocious sexual development may occur in boys and virilisation in girls, and premature epiphyseal closure may occur in both sexes. In the event of androgenic effects, danazol should be withdrawn, as they may prove irreversible on continued use. Breast feeding. Licensed product information warns that danazol should be avoided in breast-feeding women because of the theoretical potential for androgenic effects in the infant. Delmadinone acetate is a progestogen with anti-androgenic and anti-oestrogenic activity. It is used as an anti-androgen Porphyria. The Drug Database for Acute Porphyria, com­ in veterinary practice. piled by the Norwegian Porphyria Centre (NAPOS) and the Porphyria Centre Sweden, classifies danazol as prob­ ably porphyrinogenic; it should be prescribed only for compelling reasons and precautions should be considered in all patients 1 L The Drug Database for Acute Porphyria. Available at: http://www. drugs-porphyria.org {accessed 06/10/11) Pregnancy. Reports of masculinisation of female infants Uses and Administration born to mothers who had received danazol during Like cetrorelix (p. 2257.2), degarelix is a gonadorelin pregnancy.1-3 (gonadotrophin-releasing hormone) antagonist. It is used to I. Shaw RW, Farquhar JW. Female pseudohermaphroditism associated reduce testosterone concentrations in the hormonal therapy with danazol exposure in utero: case report. Br J Obstet Gynaecol l984; 91: of advanced prostate cancer (p. 712.3 ). Degarelix is given as 386-9. the acetate, but doses are expressed in terms of the base. It is 2. Kingsbury AC. Danazol and fetal masculinization: a warning. Med J Aust 1985; 143: 410-1 1. given as a subcutaneous depot injection in the abdominal 3. Brunskill PJ. The effects of fetal exposure to danazol. Br J Obstet Gynaecol area. An initial dose of degarelix 240 mg is given in two Deslorelin is an analogue of gonadorelin (p. 2280.2) that has 1992; 99: 212-1 5. separate injections of 120 mg, as a solution of 40 mg/mL. been investigated in the treatment of precocious puberty, Maintenance doses of 80 mg are then given once every 28 short stature, prostate cancer, and endometriosis. days, as a solution of 20 mg/mL. References. Interactions I. Anonymous. Deslorelin: D-Trp-LHRH-PEA, LHRH agonist analogue, Therapy with danazol may inhibit the hepatic metabolism of Van Poppel H, et a!. Degarelix: a novel gonadotropin-releasing hormone Somagard. Drugs R D 1999; 2: 420-2. several drugs including carbamazepine (see p. 517.3), (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, 2. Klein KO, et al. Increased final height in precocious puberty aher long­ term treatment with LHRH agonists: the National Institutes of Health ciclosporin (see below), and possibly tacrolirnus (see phase 2 dosage-finding study in the treatment of prostate cancer. Bur Urol 2008; 54: 805-13. experience. J Clin Endocrinol Metab 2001; 86: 471 1-16. p. 1973.2). Danazol may also enhance the effects of warfarin 2. Gittelman M, et a!. Degarelix Study Group. A 1-year, open label, 3. Yanovski JA, et al. Treatment with a luteinizing hormone-releasing (see Sex Hormones under Warfarin, p. 1535.1). Introduc­ randomized phase II dose finding study of degarelix for the treatment of hormone agonist in adolescents with short stature. N Engl J Med 2003; 348: tion of danazol appeared to reduce the maintenance prostate cancer in North America. J Urol (Baltimore) 2008; 180: 1986-92. 908-17. 4. Weise M, et a!. Determinants of growth during gonadotropin-releasing requirement for alfacalcidol (see p. 2118.1). Rhabdomyo­ 3. Klotz L, et al. The efficacy and safety of dcgarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in hormone analog therapy for precocious puberty. J Clin Endocrinol Metab Iysis has been attributed to use of danazol with statins (see patients with prostate cancer. BJU Int 2008; 102: 1531-8. 2004; 89: 103-7. p. 1495.2). 4. Frampton JE, Lyseng-Williamson KA. Degarelix. Drugs 2009; 69 1967- : 76. 5. Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist Ciclosporin. Danazol may raise ciclosporin concentrations for the management of prostate cancer. Clin Ther 2009; 31: 2312-3 1. (see p. 1955.1), possibly by inhibiting its metabolism. A case of fatal acute hepatic failure due to centrilobular massive hepatic necrosis was attributed to danazol in a Adverse Effects and Precautions patient already taking ciclosporin.1 Danazol may have raised Injection site reactions of pain and erythema are very the ciclosporin concentrations in this case, but the authors common with degarelix, while swelling, induration, and speculated that an alternative interaction between the two nodules occur less often but may still be common. Transient drugs might have played a role in this reaction to danazol. chills, fever, and flu-like symptoms may occur hours after 1. Hayashi T, et a!. Fatal acute hepatic failure induced by danazol in a dosing. Other effects commonly reported for degarelix have patient with endometriosis and aplastic anemia. J Gastroenterol2001; 36: included increases in liver enzyme values, insomnia, 783-6. dizziness, headache, and gastrointestinal disturbances. Hot flushes are a very common consequence of androgen Pharmacokinetics suppression by degarelix, while night sweats, fatigue, and weight gain are common complaints. Degarelix can also Ph. Eur. 8: (Desogestrel). A white or almost white, Danazol is absorbed from the gastrointestinal tract and contribute to loss of libido, erectile dysfunction, testicular crystalline powder. Practically insoluble in water; freely metabolised in the liver; absorption is markedly increased if atrophy, and gynaecomastia. Long-term androgen depriva­ soluble in dehydrated alcohol and in dichloromethane; very it is taken with food. A plasma elimination half-life of 3 to 6 tion therapy in general has also been associated with soluble in methyl alcohol. hours has been reported after a single dose, but is increased prolongation of the QT interval and decreases in bone to about 26 hours with repeated dosing. Ethisterone, 2- density. hydroxymethylethisterone, and I 7 -hydroxymethylethis­ Uses and Administration terone are the major metabolites, though none have Desogestrel
Recommended publications
  • Package Leaflet: Information for the Patient Desogestrel Rowex

    Package Leaflet: Information for the Patient Desogestrel Rowex

    Package leaflet: Information for the patient Desogestrel Rowex 75 microgram Film-coated tablets desogestrel Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Desogestrel Rowex is and what it is used for 2. What you need to know before you take Desogestrel Rowex 4. Possible side effects 5. How to store Desogestrel Rowex 6. Contents of the pack and other information 1. What Desogestrel Rowex is and what it is used for Desogestrel Rowex used to prevent pregnancy. There are 2 main kinds of hormone contraceptive. - The combined pill, "The Pill", which contains 2 types of female sex hormone an oestrogen and a progestogen, - The progestogen-only pill, POP, which doesn't contain an oestrogen. Desogestrel Rowex is a progestogen-only-pill (POP). Desogestrel Rowex contains a small amount of one type of female sex hormone, the progestogen desogestrel. Most POPs work primarily by preventing the sperm cells from entering the womb but do not always prevent the egg cell from ripening, which is the main way that combined pills work.
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In

    Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In

    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Desogestrel-Only Pill (Cerazette)

    Desogestrel-Only Pill (Cerazette)

    J Fam Plann Reprod Health Care: first published as 10.1783/147118903101197593 on 1 July 2003. Downloaded from Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit A unit funded by the FFPRHC and supported by the University of Aberdeen and SPCERH to provide guidance on evidence-based practice New Product Review (April 2003) Desogestrel-only Pill (Cerazette) Journal of Family Planning and Reproductive Health Care 2003; 29(3): 162–164 Evidence from a randomised trial has shown that a 75 mg (microgrammes) desogestrel pill inhibits ovulation in 97% of cycles. Thus, on theoretical grounds, we would expect the desogestrel pill to be more effective than existing progestogen- only pills (POPs). However, Pearl indices from clinical trials comparing it to a levonorgestrel POP were not significantly different. Therefore an evidence-based recommendation cannot be made that the desogestrel pill is different from other POPs in terms of efficacy, nor that it is similar to combined oral contraception (COC) in this respect. An evidence-based recommendation can be made that the desogestrel-only pill is similar to other POPs in terms of side effects and acceptability. The desogestrel-only pill is not recommended as an alternative to COC in routine practice, but provides a useful alternative for women who require oestrogen-free contraception. In clinical trials: l Ovulation was inhibited in 97% of cycles at 7 and 12 months after initiation. l The Pearl index was 0.41 per 100 woman-years, which was not significantly different from a levonorgestrel-only pill. However, the trial providing these data was too small to detect a clinically important difference.
  • WSAVA List of Essential Medicines for Cats and Dogs

    WSAVA List of Essential Medicines for Cats and Dogs

    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
  • Contraceptive Choices for Women with Inflammatory Bowel Disease

    Contraceptive Choices for Women with Inflammatory Bowel Disease

    J Fam Plann Reprod Health Care: first published as 10.1783/147118903101197782 on 1 July 2003. Downloaded from Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit A unit funded by the FFPRHC and supported by the University of Aberdeen and SPCERH to provide guidance on evidence-based practice FFPRHC Guidance (July 2003) Contraceptive Choices for Women with Inflammatory Bowel Disease Journal of Family Planning and Reproductive Health Care 2003; 29(3): 127–135 This Guidance provides information on the effects of inflammatory bowel disease (IBD) in women of reproductive age with particular reference to contraceptive choices, fertility and pregnancy. For comprehensive advice on the management of patients with IBD, readers should refer to guidelines from the British Society for Gastroenterology.1 A key to the grades of recommendations, based on levels of evidence, is given at the end of this document. Details of the methods used by the Clinical Effectiveness Unit (CEU) in developing this Guidance, and evidence tables summarising the research basis of the recommendations, are available on the Faculty website (www.ffprhc.org.uk). Abbreviations used include: 5-aminosalicylic acid (5-ASA), body mass index (BMI), bone mineral density (BMD), combined oral contraception (COC), confidence interval (CI), copper-bearing intrauterine contraceptive device (IUD), Crohn’s disease (CD), depot medroxyprogesterone acetate (DMPA), dual X-ray absorptiometry (DEXA), emergency contraception (EC), gastrointestinal (GI), incidence rate ratio (IRR), inflammatory bowel disease (IBD), levonorgestrel-releasing intrauterine system (IUS), odds ratio (OR), progestogen-only emergency contraception (POEC), progestogen-only pill (POP), anti-tumour necrosis factor-alpha (anti- TNF-a), ulcerative colitis (UC), venous thromboembolism (VTE), World Health Organization (WHO).
  • Connecticut Medicaid

    Connecticut Medicaid

    ACNE AGENTS, TOPICAL ‡ ANGIOTENSIN MODULATOR COMBINATIONS ANTICONVULSANTS, CONT. CONNECTICUT MEDICAID (STEP THERAPY CATEGORY) AMLODIPINE / BENAZEPRIL (ORAL) LAMOTRIGINE CHEW DISPERS TAB (not ODT) (ORAL) (DX CODE REQUIRED - DIFFERIN, EPIDUO and RETIN-A) AMLODIPINE / OLMESARTAN (ORAL) LAMOTRIGINE TABLET (IR) (not ER) (ORAL) Preferred Drug List (PDL) ACNE MEDICATION LOTION (BENZOYL PEROXIDE) (TOPICAL)AMLODIPINE / VALSARTAN (ORAL) LEVETIRACETAM SOLUTION, IR TABLET (not ER) (ORAL) • The Connecticut Medicaid Preferred Drug List (PDL) is a BENZOYL PEROXIDE CREAM, WASH (not FOAM) (TOPICAL) OXCARBAZEPINE TABLET (ORAL) listing of prescription products selected by the BENZOYL PEROXIDE 5% and 10% GEL (OTC) (TOPICAL) ANTHELMINTICS PHENOBARBITAL ELIXIR, TABLET (ORAL) Pharmaceutical and Therapeutics Committee as efficacious, BENZOYL PEROXIDE 6% CLEANSER (OTC) (TOPICAL) ALBENDAZOLE TABLET (ORAL) PHENYTOIN CHEW TABLET, SUSPENSION (ORAL) safe and cost effective choices when prescribing for HUSKY CLINDAMYCIN PH 1% PLEGET (TOPICAL) BILTRICIDE TABLET (ORAL) PHENYTOIN SOD EXT CAPSULE (ORAL) A, HUSKY C, HUSKY D, Tuberculosis (TB) and Family CLINDAMYCIN PH 1% SOLUTION (not GEL or LOTION) (TOPICAL)IVERMECTIN TABLET (ORAL) PRIMIDONE (ORAL) Planning (FAMPL) clients. CLINDAMYCIN / BENZOYL PEROXIDE 1.2%-5% (DUAC) (TOPICAL) SABRIL 500 MG POWDER PACK (ORAL) • Preferred or Non-preferred status only applies to DIFFERIN 0.1% CREAM (TOPICAL) (not OTC GEL) (DX CODE REQ.) ANTI-ALLERGENS, ORAL SABRIL TABLET (ORAL) those medications that fall within the drug classes DIFFERIN
  • University of Groningen Multi-Residue Analysis of Growth Promotors In

    University of Groningen Multi-Residue Analysis of Growth Promotors In

    University of Groningen Multi-residue analysis of growth promotors in food-producing animals Koole, Anneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1998 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Koole, A. (1998). Multi-residue analysis of growth promotors in food-producing animals. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 APPENDIX 1 OVERVIEW OF RELEVANT SUBSTANCES This appendix consists of two parts. First, substances that are relevant for the research presented in this thesis are given. For each substance CAS number (CAS), molecular weight (MW), bruto formula (formula) and if available UV maxima and alternative names are given. In addition, pKa values for the ß-agonists are listed, if they were available.
  • Pharmaceutical and Veterinary Compounds and Metabolites

    Pharmaceutical and Veterinary Compounds and Metabolites

    PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES High quality reference materials for analytical testing of pharmaceutical and veterinary compounds and metabolites. lgcstandards.com/drehrenstorfer [email protected] LGC Quality | ISO 17034 | ISO/IEC 17025 | ISO 9001 PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES What you need to know Pharmaceutical and veterinary medicines are essential for To facilitate the fair trade of food, and to ensure a consistent human and animal welfare, but their use can leave residues and evidence-based approach to consumer protection across in both the food chain and the environment. In a 2019 survey the globe, the Codex Alimentarius Commission (“Codex”) was of EU member states, the European Food Safety Authority established in 1963. Codex is a joint agency of the FAO (Food (EFSA) found that the number one food safety concern was and Agriculture Office of the United Nations) and the WHO the misuse of antibiotics, hormones and steroids in farm (World Health Organisation). It is responsible for producing animals. This is, in part, related to the issue of growing antibiotic and maintaining the Codex Alimentarius: a compendium of resistance in humans as a result of their potential overuse in standards, guidelines and codes of practice relating to food animals. This level of concern and increasing awareness of safety. The legal framework for the authorisation, distribution the risks associated with veterinary residues entering the food and control of Veterinary Medicinal Products (VMPs) varies chain has led to many regulatory bodies increasing surveillance from country to country, but certain common principles activities for pharmaceutical and veterinary residues in food and apply which are described in the Codex guidelines.
  • Malta Medicines List April 08

    Malta Medicines List April 08

    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
  • Rominder P.S. Suri, Phd, PE Robert F. Chimchirian & Sandhya Meduri Department of Civil & Environmental Engineering Villa

    Rominder P.S. Suri, Phd, PE Robert F. Chimchirian & Sandhya Meduri Department of Civil & Environmental Engineering Villa

    Emerging Contaminants and Water Supply – Speaker Abstracts Emerging Contaminants and Water Supply – Speaker Abstracts PRESENCE OF ESTROGEN HORMONES AND ANTIBIOTICS IN detection limits for all 12 estrogen compounds ranged from 0.1 ng L-1 to THE ENVIRONMENT 10 ng L-1 using a sample size of 1 L. Eight antibiotics and venlaflaxine Rominder P.S. Suri, PhD, PE were detected in the effluent with concentrations that ranged from 50 to Robert F. Chimchirian & Sandhya Meduri 2,930 ng L-1. Department of Civil & Environmental Engineering Twenty-one streams in Chester County, southeast Pennsylvania, were Villanova University, Villanova PA 19085 also sampled for aqueous concentrations of the above hormones and 610-519-7631 [email protected] antibiotics. Chester County represents a very diverse land use. In addition to concentrated urban developments, there are many In recent years, the detection of trace amount of pharmaceutically active agricultural farms (dairy, cattle, hog, poultry, and mushroom). The compounds (PACs) in the surface water has gained widespread watershed is comprised of about 280,000 acres that eventually drain into attention. The presence of the PACs in the natural water systems causes the Chesapeake Bay via the Susquehanna River. The results showed that ecological problems and possible adverse effects to humans. Two classes there was at least one estrogen detected in every stream sampled and six of PACs, estrogen hormones and antibiotics make their way into the estrogens were detected at three different locations. The most abundant surface waters through effluents from wastewater treatment plants and PAC was estrone, which was detected in all but one stream, with areas where animal manure and biosolids are land applied, amongst concentrations as high as 2.4 ng L-1.
  • Coordinating Investigator

    Coordinating Investigator

    Public Disclosure Synopsis Page 1 of 6 KF4248/05 12 July 2016 Confidential TITLE OF TRIAL: Safety of the oral monophasic contraceptive GRT4248 (0.02 mg ethinylestradiol/2 mg chlormadinone acetate) in comparison to 0.02 mg ethinylestradiol/0.15 mg desogestrel given for 6 medication cycles SPONSOR/COMPANY: Grünenthal GmbH, 52099 Aachen, Germany COORDINATING Milano, Italy INVESTIGATOR: TRIAL CENTER(S): Thirty-three centers in total: 11 in Germany, 4 in Spain, 5 in France, 6 in Italy, 2 in Portugal, 5 in Russia PUBLICATION Not applicable (REFERENCE): TRIAL PERIOD (YEARS): First subject enrolled: 08 NOV 2005 Last subject completed: 16 AUG 2006 Data-base lock 24 OCT 2006 PHASE OF DEVELOPMENT: Phase III OBJECTIVES: To determine the safety of 0.02 mg ethinylestradiol/2 mg chlormadinone acetate, given for 24 days each 28-day cycle in comparison to 0.02 mg ethinylestradiol/0.15 mg desogestrel given for 21 days each 28-day cycle. Each investigational medicinal product (IMP) was to be taken for 6 cycles. METHODOLOGY: Randomized, multicenter, double-blind, desogestrel-controlled, parallel group, multiple administration, Phase III trial NUMBER OF SUBJECTS: Subjects were allocated by randomization to two medication groups, one receiving 0.02 mg ethinylestradiol/2 mg chlormadinone acetate (the GRT4248 group) and one receiving 0.02 mg ethinylestradiol/0.15 mg desogestrel (the EE/DSG group). The planned and actual sizes of the two groups were: Grünenthal Public Disclosure Synopsis Page 2 of 6 Confidential KF4248/05 12 July 2016 Evaluated Medication Randomized